TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12941195
Drug: LHRH agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonists (e.g., goserelin)
Study: 10380836
Drug: Intermittent cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclical etidronate (400 mg daily for 2 weeks) and calcium (500 mg daily for 11 weeks)
Study: 8671814
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum insulin concentration
Study: 8671814
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum insulin concentration and diuretic therapy
Study: 2065824
Drug: Intensive neurodevelopmental
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive neurodevelopmental therapy (NDT)
Study: 2065824
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy alone
Study: 21055143
Drug: Regular therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular therapy
Study: 6173900
Drug: Concurrent control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent control group
Study: 30118533
Drug: Computer-Assisted Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-Assisted Implant Planning and Placement (CAIPP) - Test 1 (T1, n = 24)
Study: 30118533
Drug: Computer-Assisted Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-Assisted Implant Planning and Placement (CAIPP) - Test 2 (T2, n = 23)
Study: 26806668
Drug: Minute ventilation-targeted
Normalized name: Tagetes minuta flower oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minute ventilation-targeted adaptive servo-ventilation (MV-ASV) during sleep in addition to optimized medical therapy (active therapy)
Study: 26806668
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical therapy alone (usual care)
Study: 25153328
Drug: Daily liquorice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily liquorice consumption (glycyrrhizin dose 290‐370 mg) for two weeks
Study: 22774385
Drug: Weekly lectures
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly lectures by clinical experts (Control group).
Study: 19930245
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of propofol 2 mg/kg with supplemental doses of 0.5 mg/kg as needed, followed by normal saline infusion at 0.3 ml/kg/h.
Study: 19930245
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of propofol after initial sedation.
Study: 16334716
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with point-injection therapy
Study: 16334716
Drug: Basic neural
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic neural medical treatment
Study: 10598967
Drug: AV node
Normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV node ablation and pacemaker implantation after discontinuation of rate-control medications
Study: 10598967
Drug: AV node
Normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV node ablation and pacemaker implantation without discontinuation of antiarrhythmic rate-control drugs
Study: 10598967
Drug: Pacemaker implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacemaker implantation without AV node ablation and continuing rate-control medical therapy
Study: 7564786
Drug: Randomised consent
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised consent to experimental treatment
Study: 7564786
Drug: Randomised consent
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised consent to standard treatment
Study: 2009781
Drug: Low-dose amrinone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amrinone (0.75 mg/kg loading dose + 10 micrograms/kg/min infusion)
Study: 2009781
Drug: High-dose amrinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amrinone (2.25 mg/kg loading dose + 20 micrograms/kg/min infusion)
Study: 30919382
Drug: Early P2Y12
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early P2Y12 inhibitor loading (clopidogrel)
Study: 29975953
Drug: Thalidomide plus
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide plus chemotherapy (CAG regimen with thalidomide at a maximum dose of 200 mg/day)
Study: 29975953
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (PC) - non‐intensive regimen composed of cytarabine, aclarubicin and G‐CSF (CAG) chemotherapy
Study: 29975953
Drug: Thalidomide plus
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide plus chemotherapy
Study: 24739131
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day for 8 weeks
Study: 24739131
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day and 20 mg/day for 8 weeks
Study: 22824595
Drug: Preoperative subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative subconjunctival injection of mitomycin C (0.1 ml of 0.15 mg/ml) a day before surgery
Study: 22824595
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of mitomycin C during surgery (same concentration)
Study: 22824595
Drug: Preoperative subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative subconjunctival injection of mitomycin C
Study: 19015231
Drug: Adjunctive antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antidepressant treatment for bipolar depression
Study: 20854115
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) therapy
Study: 1597230
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (100 micrograms.min‐1)
Study: 31374191
Drug: Monthly coaching
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly coaching by physiotherapists encouraging 30 minutes of daily physical activity and 45-60 minutes of weekly exercise
Study: 25638011
Drug: secukinumab 30
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 30 mg/kg IV
Study: 25638011
Drug: secukinumab 10
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: secukinumab 10 mg/kg IV
Study: 25638011
Drug: secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 300 mg SC
Study: 18830553
Drug: Preemptive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive local analgesia (PLA) with 20 ml of 0.5% bupivacaine with 1:200,000 epinephrine
Study: 15035516
Drug: 150 mL
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL of iopamidol (300 mgI/mL) at 5 mL/second
Study: 15035516
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of iopamidol (370 mgI/mL) at 4 mL/second
Study: 9743440
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 mg starting dose, 60 mg maintenance dose once daily)
Study: 2737602
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine with HBsAg complexed by anti-HBs in hepatitis B immunoglobulin at equivalent proportions
Study: 2737602
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine with HBsAg complexed by anti-HBs in hepatitis B immunoglobulin at 10-fold antigen excess
Study: 2737602
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine with standard dosage of HBsAg (3 micrograms)
Study: 29625841
Drug: Adjuvant gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant gemcitabine 1000 mg/m2 on days 1, 8, 15 every 4 weeks for six cycles (group A)
Study: 29625841
Drug: Adjuvant PEXG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant PEXG (cisplatin 30 mg/m2, epirubicin 30 mg/m2, and gemcitabine 800 mg/m2 on days 1 and 15 every 4 weeks and capecitabine 1250 mg/m2 on days 1-28) (group B)
Study: 26328588
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) therapy with 40 mg pantoprazole b.i.d.
Study: 22699302
Drug: Anamorelin 50
Normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anamorelin 50 mg/day
Study: 19289630
Drug: Gefitinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 500 mg/day
Study: 12897327
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg or 500 mg daily)
Study: 11502792
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral androstenedione
Study: 11502792
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral androstenedione
Study: 11502792
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral androstenedione
Study: 8321259
Drug: Intrathecal chemotherapy
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal chemotherapy during the first year; cranial irradiation and intrathecal chemotherapy one year after remission for high-risk patients
Study: 8321259
Drug: Intrathecal injections
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal injections of chemotherapeutic agents and cranial irradiation for patients with central nervous system leukemia at diagnosis
Study: 23349557
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of ALA after 10 days of oral ingestion (Group C)
Study: 23349557
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of ALA (single dose) (Group B)
Study: 21140562
Drug: Cytoflavin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin as a supporting drug in CAF chemotherapy
Study: 21140562
Drug: CAF chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF chemotherapy
Study: 7631729
Drug: Modified Pereyra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Pereyra needle suspension
Study: 1497046
Drug: Home uterine
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home uterine activity monitoring and daily midwife contact
Study: 11826422
Drug: Amantadine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine therapy
Study: 350129
Drug: Amantadine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine alone or added to stable dose of levodopa
Study: 350129
Drug: Levodopa alone
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa alone or added to stable dose of amantadine
Study: 350129
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of amantadine a day
Study: 350129
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of amantadine a day
Study: 26115203
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G‐GR) 1,800 mg once daily
Study: 24118500
Drug: Supervised injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised injectable heroin treatment
Study: 24118500
Drug: Supervised injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised injectable methadone treatment
Study: 24118500
Drug: Optimised oral
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised oral methadone treatment
Study: 21784729
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 mg plus MTX
Study: 22127693
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg plus MTX
Study: 17061598
Drug: Multi-injection thoracic
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-injection thoracic paravertebral anesthesia (TPVA) with intravenous sedation
Study: 16915030
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day irbesartan
Study: 12820855
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CT examination
Study: 7718370
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections (IMI)
Study: 7257433
Drug: Metronidazole preoperative
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole preoperative preparation
Study: 28737425
Drug: Conventional buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional buccal orthodontics (20 patients)
Study: 20975285
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with high MPL content
Study: 20975285
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with lower MPL content
Study: 12867568
Drug: Early high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-dose steroids and nasal CPAP ventilation
Study: 12867568
Drug: Other three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other three treatment groups (not specified)
Study: 11336083
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg/day
Study: 11336083
Drug: Delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril 30 mg/day
Study: 24465156
Drug: MMP (multi‐ingredient
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMP (multi‐ingredient pre‐exercise workout supplement blend of creatine, betaine and a dendrobium extract)
Study: 18724865
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy with or without the use of antibiotics
Study: 18724865
Drug: Implant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant therapy in subjects with diabetes
Study: 15842586
Drug: K-Canrenoate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-Canrenoate (200 mg/day for 6 months)
Study: 15842586
Drug: No-drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug treatment (control group)
Study: 14699226
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg) and Metoclopramide (10 mg)
Study: 2258632
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta
Study: 28423407
Drug: Web-mediated follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-mediated follow-up algorithm based on weekly self-scored patient symptoms
Study: 17301652
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg ATP administered through a naso-intestinal tube
Study: 17301652
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered through a naso-intestinal tube
Study: 15110902
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of slow-release indapamide SR
Study: 2522134
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of amlodipine
Study: 15110902
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of slow-release indapamide SR + 4 mg of perindopril
Study: 15110902
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of amlodipine + 4 mg of perindopril
Study: 11244764
Drug: dopamine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: dopamine 2 mcg.kg‐1.min‐1
Study: 11244764
Drug: dobutamine 2
Normalized name: dobutamine 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: dobutamine 2 mcg.kg‐1.min‐1
Study: 8065152
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 20 mg and 10 mg of mitomycin C IV on postoperative days 0 and 1, then tegafur at 600 mg/body daily PO from postoperative week 2 for 1 year.
Study: 8065152
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 0.2 mg of mitomycin C per kg IV at 3, 6, 9, and 12 months after surgery.
Study: 3338348
Drug: Conventional intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intramuscular (IM) analgesia
Study: 22446638
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg MF59(®) adjuvanted vaccine
Study: 22446638
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg MF59(®) adjuvanted vaccine
Study: 22446638
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg non-adjuvanted vaccine
Study: 22446638
Drug: 3.75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 μg MF59(®) adjuvanted vaccine (adults)
Study: 22446638
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg MF59(®) adjuvanted vaccine (elderly)
Study: 22446638
Drug: Booster administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Booster administration after two priming doses
Study: 20033465
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MenACWY-CRM at 6 and 12 months
Study: 20033465
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of MenACWY-CRM at 12 months
Study: 20033465
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of MenC at 12 months
Study: 20033465
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MenACWY-CRM
Study: 20033465
Drug: MenACWY-CRM (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (two doses)
Study: 20033465
Drug: MenC (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenC (one dose)
Study: 15221207
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 microg capsules daily)
Study: 19583878
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule daily)
Study: 1827019
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg once daily
Study: 8061848
Drug: Spirapril 6
Normalized name: spirapril 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 6 mg once daily
Study: 2455089
Drug: Pharmacological protection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological protection with coenzyme Q (5 mg/kg) and aprotinin (10,000 KIU/kg) administered intravenously every 12 hours post-surgery and a single dose intraoperatively.
Study: 30285125
Drug: β2-agonist terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: β2-agonist terbutaline (0.2 to 0.4 mg)
Study: 29066444
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 200,000 IU followed by monthly 100,000 IU doses (n=71)
Study: 29066444
Drug: Placebo monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo monthly (n=79)
Study: 24377531
Drug: Goshajinkigan (GJG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goshajinkigan (GJG) 7.5 g/day
Study: 24377531
Drug: Mecobalamin (B12)
Normalized name: mecobalamin / vitamin B12
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecobalamin (B12) 1500 μg/day
Study: 25511923
Drug: Erlotinib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib maintenance therapy
Study: 21919119
Drug: Emotionally Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotionally Focused Therapy (EFT)
Study: 10037386
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy transurethral microwave therapy
Study: 8625038
Drug: Methyl‐lomustine/5‐FU/Leucovorin (MFL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl‐lomustine/5‐FU/Leucovorin (MFL) regimen (methyl‐lomustine 110 mg/m2 on Day 1 of each 8-week cycle, 5‐FU 600 mg/m2 weekly, Leucovorin 500 mg/m2 weekly)
Study: 8625038
Drug: 5‐FU and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU and Leucovorin (FL) regimen (5‐FU 600 mg/m2 weekly, Leucovorin 500 mg/m2 weekly)
Study: 2158151
Drug: Heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000 IU b.i.d.)
Study: 31780589
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with antipsychotic medication
Study: 24125620
Drug: Levocarnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine (3 g within 250 ml normal saline for intravenous infusion)
Study: 24125620
Drug: Conventional anti‐heart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti‐heart failure drugs
Study: 29365058
Drug: 6-monthly 18FDG-PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-monthly 18FDG-PET/CT